xml version="1.0" encoding="UTF-8"?        Document  

false0000721371  0000721371   2020-01-21 2020-01-21  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 21, 2020 

Cardinal Health, Inc. 

(Exact Name of Registrant as Specified in Charter)

[DATA_TABLE_REMOVED]

7000 Cardinal Place, Dublin, Ohio 43017 

(Address of Principal Executive Offices) (Zip Code)

(614) 757-5000 

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[DATA_TABLE_REMOVED]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

Stuart G. Laws, Senior Vice President and Chief Accounting Officer, has notified Cardinal Health, Inc. (the “Company”) that he will retire effective August 31, 2020. The Company’s Board of Directors has appointed Patricia M. English as Senior Vice President and Chief Accounting Officer, effective September 1, 2020.

Ms. English, 40, has served as Vice President, Pharmaceutical Segment Accounting since January 2019. Prior to that, she served as Vice President, Medical Segment Accounting from March 2015 to December 2018 and as Director, Pharmaceutical Distribution Accounting from June 2011 to March 2015.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]

3